{"url_path":"/sec/pbm/10-k/2026/item-16a","section_key":"item-16a","section_title":"Item 16A AUDIT COMMITTEE FINANCIAL EXPERT","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","accession_number":"0001213900-26-070607","cik":"0001985062","ticker":"PBM","issuer_name":"PSYENCE BIOMEDICAL LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","primary_entity_key":"0001985062","primary_entity_name":"PSYENCE BIOMEDICAL LTD."},"word_count":106,"has_tables":true,"body_markdown":"** **\n\nITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT\n\n \n\nThe Company’s Audit Committee consists of\nMarc Balkin, Graham Patrick and Sashank Pillay. Mr. Balkin is an “audit committee financial expert” within the meaning\nof SEC regulations. Mr. Balkin serves as the chairperson of the Audit Committee. Each member of the Audit Committee can read and\nunderstand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the Board\nwill examine each Audit Committee member’s scope of experience and the nature of their employment. For a description of the education\nand experience of each member of the Audit Committee, see “Item 6A. Directors, Senior Management and Employees.”"}